Slide 1: H1 2026 Results
H1 2026 Results Thomas Meier, CEO Stefan Bauerreis, CFO August 12, 2026
Slide 2: Agenda
Agenda 1 Executive Summary 2 Acquisition Caelo 3 Financial Overview 4 Focus Activities & Take Aways 5 Q&A H1 2026 Results 2 2
Slide 3: Executive Summary
01 Executive Summary
Slide 4: H1 2026: Robust revenue growth, while profitability decreased
H1 2026: Robust revenue growth, while profitability decreased €1,075m €44.0m 4.1% Revenue +8.4% YoY EBITDA pre EBITDA pre margin (PY: 4.7%) first half-year > €1bn (−5.1% YoY) Focus points H2 focus: profitability, cash Avanti Medios! implementation Strategic Milestone with the conversion and operatio
Slide 5: Group: Revenue Grew but Lower EBITDA pre Margin – Guidance revised end of July
Financial overview Q2/25 vs Q2/26 Group: Revenue Grew but Lower EBITDA pre Margin – Guidance revised end of July Revenue (€m) EBITDA pre¹ (€m/%) QoQ growth 7.9% QoQ growth -2.3% • Organic revenue growth in all 549 547 operational segments 24,0 538 23,1 23,3 22,7 22,7 • EBITDA pre margin lower than P
Slide 6: Business Highlights
Business Highlights 1 2 3 Pharmaceutical Supply Patient Specific Therapies International Business • Revenue growth in H1 (+8.5%) • Revenue growth in H1 (+8.5%) • Revenue growth in H1 • Price pressure on specific • Margin improvement in Q2 vs. (+6.9%) high-margin medicines Q1 as a result of operation
Slide 7: Regulatory Radar
Financials Regulatory Radar Legislation Status / read for Medios Impact DAV ended the GKV cytostatics-invoicing contract (Mar 31); current 1 Drug price regulation („Hilfstaxe“) pricing holds, arbitration ongoing. Agreement expected 2026 — limited forecast assumes no substantial reimbursement change
Slide 8: Acquisition Caelo
02 Acquisition Caelo
Slide 9: Executive Summary
Executive Summary Proposed transaction: • Acquisition of majority stake (74%) of Caesar & Loretz GmbH (Caelo), including put-/ call-option for the remaining 26% of shares • Total consideration € 9.4m consisting of: − € 7.9m for 74% of the shares − € 1.5m control premium, to be netted against future
Slide 10: Caesar & Loretz GmbH at a Glance
Caesar & Loretz GmbH at a Glance The company: Key facts Production sites • Caesar & Loretz GmbH (Caelo) is the leading supplier of APIs, excipients and other raw materials in Germany. Founded Headquarter • The company is active in the trade of raw materials, 1886 Hilden, Germany narcotics and OTC-pr
Slide 11: Strategic Rationale for the Acquisition
Strategic Rationale for the Acquisition • How the deal fits our strategic objectives • Strengthening our core market in Germany through integration of value-added services for pharmacies in Germany • Acquisition of clear market leader in Germany and a lighthouse brand in the German pharmacy market •
Slide 12: Financial Assessment of the Transaction
Financial Assessment of the Transaction Synergies (in € million] • Focus on synergies from operational cooperation between Magis +1,3 Pharma, Metapharmaceutical and Caelo +1,0 • Providing additional added value for our customers through +2,1 compounding services as well as supply of compounding +1,7
Slide 13: Next Steps
Next Steps • Yesterday (11.08.2026): Signing of share purchase agreement (SPA) • In the following days: Notification to the Competition Authorities and review of the acquisition by the Federal Cartel Office (Bundeskartellamt) • Intended Closing: After final approval from the Federal Cartel Office 13
Slide 14: Financial Overview
03 Financial Overview
Slide 15: H1 2026 – Strong Revenue Growth and temporarily low Cash Flow
Financial overview H1 2026 – Strong Revenue Growth and temporarily low Cash Flow In € million H1 2026 H1 2025 ∆ in % / ppt Revenue 1,074.9 991.7 8.4% • Strong organic growth in revenues supported by all Gross profit1 operational segments 101.7 101.1 0.6% gross margin in % 9.5% 10.2% -0.7ppt • Decrea
Slide 16: H1 2026 – Revenue Growth in All Operational Segments
Financial overview H1 2026 – Revenue Growth in All Operational Segments Pharmaceutical Patient-specific International Services Group Supply 'PS' Therapies 'PST' Business 'IB' YoY in € million H1 26 H1 25 H1 26 H1 25 H1 26 H1 25 H1 26 H1 25 H1 26 H1 25 Segment revenue – 868.4 800.1 119.6 110.2 86.7 8
Slide 17: PS: Revenue up while EBITDA pre decreased
Financial overview Q2/25 vs Q2/26 PS: Revenue up while EBITDA pre decreased Revenue external (€m) EBITDA pre¹ (€m/%) QoQ growth 8.1% QoQ growth -21.1% • Good sales development in all areas 14,6 449 13,8 444 • Continuous price decreases of selected 439 12,4 products overall led to lower gross 11,8 12
Slide 18: PS: YoY H1 2026 EBITDA pre Bridge
Financial overview PS: YoY H1 2026 EBITDA pre Bridge €€ 26.4 mm 26,3755 €€0.8 ,800mm € 23.6 m € 23,5755 m -€ 2,700 m -€ ,900 m -€ 2.7 m -€ 0.9 m EBITDA pre Continued price New business OPEX EBITDA pre prior year drop of various (Novartis and esp. (sales commissions, actual products Cannabis) personn
Slide 19: PST: Revenue and EBITDA pre growth
Financial overview Q2/25 vs Q2/26 PST: Revenue and EBITDA pre growth Revenue external (€m) EBITDA pre¹ (€m/%) QoQ growth 8.6% QoQ growth 5.4% 7 50 • Revenue growth in H1 (+8.5%), 6,3 6,1 6,1 45 supported by higher production 6 5,7 volumes across all customer segments 60 5,4 59 40 • Sequential margin
Slide 20: PST: YoY H1 2026 EBITDA pre Bridge
Financial overview PST: YoY H1 2026 EBITDA pre Bridge € 1.5 m € 1,500 m € 12.1 m € 11.5 m € 12,0600 m € 11,4750 m -€ ,8850 m -€ 0.9 m -€ ,600 m -€ 0.6 m -€ ,600 m -€ 0.6 m EBITDA pre Volume Drug price Increase in Others EBITDA pre prior year effect regulation personnel costs (external services, actu
Slide 21: IB: Revenue up, EBITDA pre Margin above PY level
Financial overview Q2/25 vs Q2/26 IB: Revenue up, EBITDA pre Margin above PY level Revenue external (€m) EBITDA pre¹ (€m/%) QoQ growth 5.1% QoQ growth 17.0% 9 50 • Revenue growth in Q2 2026 (+4.8% vs 8,2 45 8 7,7 45 Q2 2025) 7,3 7,1 44 7 6,5 40 • Q2 EBITDA pre up to €7.7m (Q2 2025: 6,3 €6.5m), suppo
Slide 22: IB: YoY H1 2026 EBITDA pre Bridge
Financial overview IB: YoY H1 2026 EBITDA pre Bridge € 4.2 m € 4,200 m € 0.8 m € ,800 m -€ 1,600 m € 0.7 m € 13.9 m € 13.8 m -€ 1.6 m € ,700 m € 13,9275 m € 13,8275 m -€ 1,700 m -€ 1.7 m -€ 1,400 m -€ ,900 m -€ 1.4 m -€ 0.9 m EBITDA pre Volume Disinvestments Disinvestments Higher material Wage Perso
Slide 23: Medios Group: Revision of Guidance 2026 as of July 28, 2026
Financial overview Medios Group: Revision of Guidance 2026 as of July 28, 2026 Sales EBITDA pre Pharmaceutical Supply (€bn) (€m) • Price pressure on specific high-margin medicines in the market to continue in H2 2026 2500 120 • Implication of new law (GKV- Beitragssatzstabilisierungsgesetz) with neg
Slide 24: Focus activities & Take-aways
04 Focus activities & Take-aways
Slide 25: Focus Activities 2026 — status after H1
Strategy Cornerstones Focus Activities 2026 — status after H1 One Team Operational Accelerate Selective M&A Medios Excellence organic growth activities Harmonize business & Network optimization Increase compounding Value accretive add-on planning processes; based on a Capital business growth rate ac
Slide 26: Medios Next Level
Medios Next Level Medios 2nd Capital Markets Day September 29, 2026 | Breda, The Netherlands Welcome at Ceban and network dinner on Sep 28 Strategy & vision | business deep dives | mid-term ambition | site tour Ceban 26
Slide 27: Key takeaways
Key takeaways 1 2 3 Broad-based PST with margin- Acquisition of growth improvement Caelo Revenue up 8.4% to First visible results of our Strategic milestone to €1,075m — the first half- operational excellence broaden portfolio towards year above €1bn, with all initiative Avanti Medios! German pharma
Slide 28: Contact
Contact Katrin Neuffer Director Investor & Communications Phone +49 30 232 566 800 katrin.neuffer@medios.group 28
Slide 29: Disclaimer
Disclaimer This presentation has been produced by Medios AG (the „Company“). The facts and information The forward-looking statements, including but not limited to assumptions, opinions and views of contained herein are as up to date as is reasonably possible and are subject to revision in the the C